Observational study of effects of HIV acquisition and antiretroviral treatment on biomarkers of systemic immune activation.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2024
Historique:
received: 14 07 2023
accepted: 14 05 2024
medline: 8 7 2024
pubmed: 8 7 2024
entrez: 8 7 2024
Statut: epublish

Résumé

To assess whether biomarkers of systemic inflammation are associated with HIV acquisition or with the timing of ART initiation ("immediate", at diagnosis, versus "deferred", at 24 weeks post-diagnosis) in men-who-have-sex-with-men (MSM) and transgender women, we conducted a retrospective study comparing inflammatory biomarkers in participants' specimens collected before infection and after ≥2 years of effective ART. We measured biomarkers in four longitudinally collected plasma, including two specimens collected from each participant before and two after HIV acquisition and confirmed ART-suppression. Biomarkers were quantified by enzyme-linked immuno-assay or Meso Scale Discovery. When evaluating systematic variation in these markers over time, we found that multiple biomarkers consistently varied across participants' two pre-infection or two post-ART-suppression specimens. Additionally, we compared changes in biomarkers after vs before HIV acquisition. Across 47 participants, the levels of C-reactive protein (CRP), monocyte chemo-attractant protein-1, tumor necrosis factor-α and interferon gamma-induced protein-10 significantly increased while leptin and lipopolysaccharide binding protein (LBP) significantly decreased following HIV infection. Randomization to deferred-ART initiation was associated with greater increases in CRP and no decrease in LBP. Acquisition of HIV appeared to induce systemic inflammation, with elevation of biomarkers previously associated with infections and cardiovascular disease. Initiation of ART during the early weeks of infection tempered the increase in pro-inflammatory biomarkers compared to delaying ART for ~24 weeks after HIV diagnosis. These findings provide insight into potential mediators by which immediate-ART initiation improves health outcomes, perhaps because immediate-ART limits the size of the HIV reservoir or limits immune dysregulation that in turn trigger systemic inflammation.

Identifiants

pubmed: 38976697
doi: 10.1371/journal.pone.0288895
pii: PONE-D-23-18653
doi:

Substances chimiques

Biomarkers 0
Acute-Phase Proteins 0
C-Reactive Protein 9007-41-4
lipopolysaccharide-binding protein 0
Anti-HIV Agents 0
Carrier Proteins 0
Membrane Glycoproteins 0

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0288895

Informations de copyright

Copyright: © 2024 Kosmider et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Auteurs

Ewelina Kosmider (E)

Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.

Jackson Wallner (J)

Seattle Children's Research Institute, Seattle, Washington, United States of America.

Ana Gervassi (A)

Seattle Children's Research Institute, Seattle, Washington, United States of America.

Rachel A Bender Ignacio (RA)

Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
Department of Medicine, University of Washington, Seattle, Washington, United States of America.
Department of Global Health, University of Washington, Seattle, Washington, United States of America.

Delia Pinto-Santini (D)

Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.

German Gornalusse (G)

Department of Obstetrics & Gynecology, University of Washington, Seattle, Washington, United States of America.

Urvashi Pandey (U)

Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
Department of Obstetrics & Gynecology, University of Washington, Seattle, Washington, United States of America.

Florian Hladik (F)

Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
Department of Medicine, University of Washington, Seattle, Washington, United States of America.
Department of Obstetrics & Gynecology, University of Washington, Seattle, Washington, United States of America.

Paul T Edlefsen (PT)

Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.

Javier R Lama (JR)

Department of Global Health, University of Washington, Seattle, Washington, United States of America.
Asociación Civil Impacta Salud y Educación, Lima, Perú.

Ann C Duerr (AC)

Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.

Lisa M Frenkel (LM)

Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
Seattle Children's Research Institute, Seattle, Washington, United States of America.
Department of Medicine, University of Washington, Seattle, Washington, United States of America.
Department of Global Health, University of Washington, Seattle, Washington, United States of America.
Department of Pediatrics, University of Washington, Seattle, Washington, United States of America.
Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH